Elucidating the effect of camel α-lactalbumin in modulating obesity-related metabolic disorders in an obese rat model
- PMID: 39793836
- DOI: 10.1016/j.ijbiomac.2025.139693
Elucidating the effect of camel α-lactalbumin in modulating obesity-related metabolic disorders in an obese rat model
Abstract
Camel α-Lactalbumin (α-LACc) has been shown to exert bioactivities for Reactive oxygen species (ROS) scavenging and anti-inflammation, showing the ability to treat obesity-related metabolic disorders. Herein, we present a novel process to purify α-LACc in a single chromatographic step from camel whey in a flow-through format. We also demonstrate the role of α-LACc modulation strategies for the treatment of obesity. An in-vivo study was systematically carried-out, in which an intragastric administration of α-LACc in rats experiencing obesity showed ameliorating effect on hepatic steatosis and dyslipidemia. In addition, we demonstrated that the reduction of inflammation and oxidative stress by α-LACc was effective, and importantly, the enhancement of antioxidant defenses was achieved. Furthermore, we found that the peroxynitrite scavenging ability of α-LACc could help restore the hepatorenal function. Finally, we showed that α-LACc could improve insulin resistance-associated glucose metabolism and insulin sensitivity disorders caused by obesity. This work has developed a novel one-step purification process of α-LACc from camel whey without the use of organic solvents. Our purified α-LACc may serve as a promising therapeutic agent in the treatment of obesity-related metabolic disorders by synergistically alleviating lipid accumulation, inflammation, oxidative stress and insulin sensitivity.
Keywords: Anti-obesity; Camel α-Lactalbumin; Purification.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no competing financial interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
